Cidara Therapeutics, Inc. (CDTX) is a publicly traded Healthcare sector company. As of May 20, 2026, CDTX trades at $221.38 with a market cap of $6.96B and a P/E ratio of -8.28. CDTX moved +0.03% today. Year to date, CDTX is +228.02%; over the trailing twelve months it is +731.63%. Its 52-week range spans $10.14 to $221.42. Analyst consensus is buy with an average price target of $221.50. Rallies surfaces CDTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CDTX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CDTX recently traded at $221.38. Market cap is $6.96B. P/E ratio is -8.28. Revenue is $1.27M.
| Metric | Value |
|---|---|
| Price | $221.38 |
| Market Cap | $6.96B |
| P/E Ratio | -8.28 |
| EPS | $-26.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $221.42 |
| 52-Week Low | $10.14 |
| Volume | 2.69M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.27M |
| Net Income | $-169.83M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $1.27M | $-169.83M | $-26.75 |
| 2023 | $63.91M | $-22.93M | $-0.26 |
| 2022 | $64.29M | $-29.80M | $-0.43 |
| 2021 | $49.57M | $-42.47M | $-0.81 |
11 analysts cover CDTX: 1 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $221.50.